胰高血糖素样肽-1受体激动剂与年龄相关性黄斑变性
这项回顾性队列研究利用多中心电子健康记录数据,纳入55岁及以上超重或肥胖但无糖尿病的患者,比较使用GLP-1RA(利拉鲁肽或司美格鲁肽)与其他减重药物者发生非渗出性AMD及进展为渗出性AMD的风险。倾向评分匹配后,GLP-1RA使用与5年、7年和10年非渗出性AMD风险降低相关,但与进展为渗出性AMD无差异。
要点
- 在超重或肥胖的非糖尿病人群中,GLP-1RA使用与5年、7年、10年非渗出性AMD风险降低相关。
- GLP-1RA使用与已存在非渗出性AMD者进展为渗出性AMD无差异。
- 作者认为这些发现可能为未来评估GLP-1RA在非糖尿病人群中眼部效应的随机试验提供信息。
核心结论
- 在超重或肥胖但无糖尿病人群中,GLP-1RA使用与发生非渗出性AMD风险降低相关,但与已存在非渗出性AMD者进展为渗出性AMD无关联。
研究设计与样本
- 回顾性队列研究,使用多中心TriNetX全球协作网络的电子健康记录数据,纳入2004年1月至2025年7月诊断为超重或肥胖但无糖尿病的55岁及以上患者。
- 主要分析排除已存在非渗出性AMD的患者,次要分析纳入已存在非渗出性AMD的患者但排除已存在渗出性AMD的患者。
- 采用倾向评分匹配平衡基线人口学特征和合并症,数据于2025年3月21日和2025年8月2日分析。
主要发现
- 共纳入91 408例患者;主要分析倾向评分匹配后,GLP-1RA队列和OWLD队列各45 704例。
- GLP-1RA队列包括35 753例(78.2%)女性和7852例(17.2%)男性,平均(SD)年龄61.1(5.76)岁;OWLD队列包括35 732例(78.2%)女性和7815例(17.1%)男性,平均(SD)年龄61.0(5.86)岁。
- 主要分析中GLP-1RA队列和OWLD队列所有变量的协变量平衡均达到。
- 与OWLD相比,GLP-1RA使用与5年非渗出性AMD风险降低相关(RR,0.16;95%CI,0.10-0.28;P < .001)、7年(RR,0.13;95%CI,0.08-0.22;P < .001)和10年(RR,0.09;95%CI,0.05-0.16;P < .001)。
- 进展为渗出性AMD未见差异。
关键数值与推荐
- 主要结局为5年、7年和10年发生非渗出性AMD,次要结局为10年进展为渗出性AMD。
- 暴露为处方GLP-1RA(利拉鲁肽或司美格鲁肽)或OWLD(包括氯卡色林、西布曲明、司美拉诺肽、芬氟拉明、马吲哚、奥利司他、芬特明和安非拉酮)。
- 计算风险比(RR)及95%CI,采用标准化均数差评估匹配后协变量平衡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for weight loss, but their ocular effects in nondiabetic individuals remain unclear. Prior studies suggest GLP-1RA use reduced age-related macular degeneration (AMD) risk in patients with diabetes, but applicability to nondiabetic populations is unknown. OBJECTIVE: To evaluate the risk of developing nonexudative AMD and its progression to exudative AMD among patients with obesity but not diabetes prescribed GLP-1RAs compared with those prescribed other weight-loss drugs (OWLDs). DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used electronic health record data obtained from the multicenter TriNetX Global Collaborative Network on patients aged 55 years or older diagnosed with overweight or obesity but not diabetes from January 2004 to July 2025. For the primary analysis, patients with preexisting nonexudative AMD were excluded. For the secondary analysis, patients with preexisting nonexudative AMD were included, while those with preexisting exudative AMD were excluded. Propensity score matching balanced baseline demographics and comorbidities. Data were analyzed on March 21, 2025, and August 2, 2025. EXPOSURES: Patients were prescribed either the GLP-1RAs liraglutide or semaglutide or OWLDs including lorcaserin, sibutramine, setmelanotide, fenfluramine, mazindol, orlistat, phentermine, and diethylpropion. MAIN OUTCOMES AND MEASURES: The primary outcome was development of nonexudative AMD at 5, 7, and 10 years. The secondary outcome was progression to exudative AMD at 10 years. Risk ratios (RRs) with 95% CIs were calculated. Standardized mean differences were used to assess covariate balance after matching. RESULTS: A total of 91 408 patients were included. After propensity score matching for the primary analysis, 45 704 patients remained in each of the GLP-1RA and OWLD cohorts. The GLP-1RA cohort included 35 753 (78.2%) females and 7852 (17.2%) males with a mean (SD) age of 61.1 (5.76) years, while the OWLD cohort included 35 732 (78.2%) females and 7815 (17.1%) males with a mean [SD] age of 61.0 (5.86) years. Covariate balance was achieved across all variables for the GLP-1RA and OWLD cohorts in the primary analysis. GLP-1RA use was associated with reduced risk of nonexudative AMD compared with OWLDs at 5 years (RR, 0.16; 95% CI, 0.10-0.28; P < .001), 7 years (RR, 0.13; 95% CI, 0.08-0.22; P < .001), and 10 years (RR, 0.09; 95% CI, 0.05-0.16; P < .001). No differences were observed in progression to exudative AMD. CONCLUSIONS AND RELEVANCE: In this cohort study, GLP-1RA use was associated with reduced risk of developing nonexudative AMD but was not associated with progression to exudative AMD among individuals with nonexudative AMD. These findings may inform future randomized trials evaluating the ocular effects of GLP-1RAs in nondiabetic populations.
引用
- Ahuja AS, Paredes AA, Young BK, et al. Glucagon-Like Peptide-1 Receptor Agonists and Age-Related Macular Degeneration. JAMA Ophthalmol. 2025. PMID: 41129133. doi:10.1001/jamaophthalmol.2025.3821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。